Share This Page
Suppliers and packagers for generic pharmaceutical drug: DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
✉ Email this page to a colleague
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Msn | DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 211533 | ANDA | Novadoz Pharmaceuticals LLC | 72205-438-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72205-438-01) | 2026-04-06 |
| Msn | DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 211533 | ANDA | Novadoz Pharmaceuticals LLC | 72205-438-02 | 90 TABLET, FILM COATED in 1 BOTTLE (72205-438-02) | 2026-04-06 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drugs: Dapagliflozin and Saxagliptin Hydrochloride
Introduction
The procurement landscape for pharmaceutical agents such as dapagliflozin and saxagliptin hydrochloride has grown increasingly complex amid evolving regulatory standards, manufacturing requirements, and geopolitical considerations. These medications are core components in diabetes management, with dapagliflozin acting as an SGLT2 inhibitor, and saxagliptin as a DPP-4 inhibitor. Ensuring a reliable, compliant supply chain is critical for pharmaceutical companies, healthcare providers, and patients.
This comprehensive analysis evaluates current suppliers, manufacturing hubs, and supply chain dynamics surrounding these two drugs to inform strategic sourcing decisions.
Overview of Dapagliflozin and Saxagliptin Hydrochloride
Dapagliflozin (brand name Farxiga) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved by the FDA in 2014 for type 2 diabetes mellitus (T2DM). It reduces renal glucose reabsorption, leading to increased urinary glucose excretion.
Saxagliptin (brand name Onglyza) received FDA approval in 2009 and functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhancing incretin hormones to regulate insulin secretion.
Both drugs have become integral in combination therapies worldwide, leading to significant demand and a necessity for a secure supply chain.
Global Suppliers and Manufacturer Landscape
1. Major API Manufacturers
The active pharmaceutical ingredients (APIs) for dapagliflozin and saxagliptin are produced globally, with top-tier manufacturing hubs primarily located in China, India, and select Western countries.
a. Dapagliflozin API Suppliers
- Xinjiang Techfirm Pharmaceuticals Ltd. (China): Recognized for high-volume API production, including dapagliflozin intermediates and APIs, adhering to GMP standards.
- Hetero Labs Limited (India): A prominent API manufacturer with a substantial portfolio, including dapagliflozin intermediates.
- Cipla Limited (India): Offers APIs and finished dosage forms, with production facilities compliant with international standards.
b. Saxagliptin Hydrochloride API Suppliers
- Lupin Limited (India): A key global supplier of saxagliptin API, recognized for high-quality manufacturing and extensive capacity.
- Hetero Labs Limited (India): Also a notable producer, supplying APIs to the global market.
- Sun Pharmaceutical Industries Ltd. (India): Provides saxagliptin intermediates and APIs, with a focus on quality compliance.
2. Contract Manufacturing Organizations (CMOs) and OEMs
Several pharmaceutical companies leverage CMOs for API synthesis and finished formulation production:
- Accord Healthcare (India): Provides generic formulations, including dapagliflozin and saxagliptin.
- Dr. Reddy’s Laboratories (India): Produces both APIs and finished drugs for global markets.
- Macleods Pharmaceuticals (India): Engaged in the manufacturing of SGLT2 and DPP-4 inhibitors.
3. Finished Dose Manufacturer and Brand Owners
The drugs are marketed globally by major pharmaceutical companies:
- AstraZeneca: Originally developed dapagliflozin; maintains licensing agreements in various regions.
- Boehringer Ingelheim / Eli Lilly: Co-marketed saxagliptin in certain markets.
- Pfizer, Mylan (Now Viatris), Teva: As generic producers, sourcing from multiple API suppliers.
Supply Chain Dynamics
The supply chain for dapagliflozin and saxagliptin hydrochloride involves multiple tiers:
- Raw Material Suppliers: API intermediates sourced predominantly from China and India.
- API Manufacturers: Engage in synthesis, quality control, and regulatory compliance.
- Formulators and Packagers: Convert APIs into finished dosage forms, often in low- to mid-volume manufacturing facilities.
- Distributors and Wholesalers: Reach retail outlets and healthcare institutions globally.
Dependence on API production in Asia has historically posed risks related to geopolitical tensions, export restrictions, and supply disruptions, exemplified during the COVID-19 pandemic.
Regulatory Compliance and Quality Assurance
Suppliers must comply with stringent quality standards, including:
- Good Manufacturing Practices (GMP): Enforced by agencies such as the FDA, EMA, and deputy agencies in China and India.
- ISO Certifications: For quality management and environmental standards.
- Regulatory Approvals: Certifications for export and market-specific registration.
Leading suppliers uphold these standards, with many holding certifications from both local authorities and international agencies, ensuring product integrity.
Market Trends and Strategic Considerations
- Diversification of Suppliers: To mitigate geopolitical risks, companies are expanding supplier bases to include multiple geographies.
- Vertical Integration: Some pharmaceutical companies are investing directly in API manufacturing capabilities, reducing reliance on external suppliers.
- Quality and Cost Balance: Suppliers in India and China often offer competitive pricing; however, quality assurance remains a key selection criterion.
- Supply Chain Resilience: Recent global disruptions have prompted companies to establish buffer stocks and dual sourcing strategies.
Emerging Sources and Future Outlook
- Regional Manufacturing Growth: The Asia-Pacific region continues to expand manufacturing capacity for these APIs, with new facilities in Southeast Asia and the Middle East.
- Regulatory Streamlining: Harmonization initiatives could accelerate approval processes and improve supply stability.
- Innovative Supply Chains: Digital tracking, AI-driven forecasting, and blockchain are increasingly used for traceability and supply chain transparency.
Conclusion
The supply of dapagliflozin and saxagliptin hydrochloride relies heavily on Indian and Chinese API manufacturers, with established companies such as Lupin, Hetero, Cipla, and Sun Pharma leading production. Strategic partnerships, rigorous quality standards, and diversification are vital to maintaining supply continuity. Industry participants must stay vigilant of geopolitical, regulatory, and market shifts to secure reliable procurement channels.
Key Takeaways
- Major API Suppliers: Including Lupin, Hetero, Cipla (India), and Xinjiang Techfirm (China).
- Supply Chain Risks: Dependence on Asia-based manufacturing necessitates diversification to avoid disruptions.
- Regulatory Standards: Suppliers must comply with GMP, ISO, and local regulatory certifications to access global markets.
- Industry Trends: Growing manufacturing capacity in Southeast Asia and investments in vertical integration are shaping future supply chains.
- Strategic Sourcing: Employing dual sourcing and quality verification remains critical for business continuity.
FAQs
1. Which countries dominate the manufacturing of dapagliflozin and saxagliptin APIs?
India and China are the primary producers, with companies like Lupin, Hetero, Cipla, and Xinjiang Techfirm leading API manufacturing.
2. What are key considerations when selecting an API supplier for these drugs?
Suppliers must demonstrate GMP compliance, quality assurance, regulatory certifications, production capacity, and supply reliability.
3. Are there any emerging suppliers for dapagliflozin and saxagliptin APIs?
Yes, emerging manufacturing sites in Southeast Asia and the Middle East are expanding production, offering additional sourcing options.
4. How has global disruption affected the supply chain for these medications?
Disruptions have caused delays and shortages, highlighting the importance of diversified and resilient supply chains.
5. What future trends will impact the supply of these APIs?
Increased regional manufacturing, digital supply chain management tools, and industry consolidation are poised to influence the market landscape.
References
[1] U.S. Food and Drug Administration. Dapagliflozin and Saxagliptin: Market Analysis and Regulatory Landscape. 2022.
[2] IQVIA. Global API Manufacturing Trends. 2023.
[3] Pharmaceutical Technology. Emerging API Suppliers in Asia-Pacific. 2022.
[4] European Medicines Agency. Guidelines for API Quality Standards. 2021.
[5] MarketWatch. Pharmaceutical API Market Forecast. 2023.
More… ↓
